{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:33:13Z","timestamp":1793118793713,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11096-025-01908-0","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T12:33:24Z","timestamp":1744720404000},"page":"654-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of SGLT2 inhibitors on health-related quality of life and functional capacity in patients with heart failure with and without diabetes: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4506-0472","authenticated-orcid":false,"given":"Mariana de Moura","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luiza Rodrigues","family":"Defante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Austreg\u00e9lio","family":"de Athayde de Hollanda Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Ximenes","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ot\u00e1vio Cosendey","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit\u00f3ria Martins","family":"Priz\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Morita Fernandes","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"21","key":"1908_CR1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"1908_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with Empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"12","key":"1908_CR3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"16","key":"1908_CR4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"key":"1908_CR5","volume":"36","author":"R Cardoso","year":"2021","unstructured":"Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinM. 2021;36: 100933.","journal-title":"EClinM"},{"key":"1908_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","volume":"8","author":"JI Fonseca-Correa","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne). 2021;8: 777861.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"1908_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"10166","key":"1908_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"22","key":"1908_CR9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"5","key":"1908_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019463","volume":"10","author":"YH Teo","year":"2021","unstructured":"Teo YH, Teo YN, Syn NL, et al. Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc. 2021;10(5): e019463.","journal-title":"J Am Heart Assoc"},{"key":"1908_CR11","doi-asserted-by":"crossref","unstructured":"Spertus JA, Jones PG, Sandhu AT, et al. Interpreting the Kansas city cardiomyopathy questionnaire in clinical trials and clinical care. JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(20):2379\u201390.","DOI":"10.1016\/j.jacc.2020.09.542"},{"issue":"36","key":"1908_CR12","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. EHJ. 2021;42(36):3599\u2013726.","journal-title":"EHJ"},{"issue":"18","key":"1908_CR13","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e895-1032.","journal-title":"Circulation"},{"issue":"7","key":"1908_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ehjqcco\/qcab079","volume":"8","author":"D Ties","year":"2022","unstructured":"Ties D, Singh TK, Zhang X, et al. What really matters: a patient-centered instrument to evaluate health-related quality of life in cardiovascular disease. Eur Heart J Qual Care Clin Outcomes. 2022;8(7):722\u20139.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"18","key":"1908_CR15","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140(18):1463\u201376.","journal-title":"Circulation"},{"issue":"11","key":"1908_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","volume":"149","author":"JJV McMurray","year":"2024","unstructured":"McMurray JJV, Docherty KF, De Boer RA, et al. Effect of Dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: the determine randomized clinical trials. Circulation. 2024;149(11):825\u201338.","journal-title":"Circulation"},{"issue":"14","key":"1908_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, et al. Effect of Dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353.","journal-title":"JAMA"},{"issue":"11","key":"1908_CR18","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360.","journal-title":"Nat Med"},{"issue":"4","key":"1908_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809\u201313.","journal-title":"Nat Med"},{"key":"1908_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","volume":"228","author":"J Jensen","year":"2020","unstructured":"Jensen J, Omar M, Kistorp C, et al. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial. Am Heart J. 2020;228:47\u201356.","journal-title":"Am Heart J"},{"issue":"6","key":"1908_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of Empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325.","journal-title":"Circulation"},{"issue":"6","key":"1908_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","volume":"42","author":"WT Abraham","year":"2021","unstructured":"Abraham WT, Lindenfeld J, Ponikowski P, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. EHJ. 2021;42(6):700\u201310.","journal-title":"EHJ"},{"issue":"10","key":"1908_CR23","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/ejhf.2560","volume":"24","author":"P Palau","year":"2022","unstructured":"Palau P, Amiguet M, Dom\u00ednguez E, et al. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction ( DAPA-VO 2): a randomized clinical trial. European J of Heart Fail. 2022;24(10):1816\u201326.","journal-title":"European J of Heart Fail"},{"key":"1908_CR24","doi-asserted-by":"crossref","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of Empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243\u201355.","DOI":"10.1016\/j.jacc.2020.11.008"},{"issue":"10","key":"1908_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","volume":"148","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Reddy YNV, Braun A, et al. Cardiac and metabolic effects of Dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation. 2023;148(10):834\u201344.","journal-title":"Circulation"},{"issue":"22","key":"1908_CR26","first-page":"1654","volume":"147","author":"MJ Hundertmark","year":"2023","unstructured":"Hundertmark MJ, Adler A, Antoniades C, et al. Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking Empagliflozin: the randomized controlled EMPA-VISION trial. Circulation. 2023;147(22):1654\u201369.","journal-title":"Controlled EMPA-VISION Trial Circulation"},{"issue":"4","key":"1908_CR27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.cjco.2023.12.002","volume":"6","author":"YR Shah","year":"2024","unstructured":"Shah YR, Turgeon RD. Impact of SGLT2 inhibitors on quality of life in heart failure across the ejection fraction spectrum: systematic review and meta-analysis. CJC Open. 2024;6(4):639\u201348.","journal-title":"CJC Open"},{"issue":"3","key":"1908_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11096-022-01504-6","volume":"45","author":"Z Guo","year":"2023","unstructured":"Guo Z, Wang L, Yu J, et al. The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials. Int J Clin Pharm. 2023;45(3):547\u201355.","journal-title":"Int J Clin Pharm"},{"key":"1908_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.942125","volume":"9","author":"D Yang","year":"2022","unstructured":"Yang D, Zhang Y, Yan J, et al. SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9: 942125.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"1908_CR30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5135","volume":"7","author":"M Gao","year":"2024","unstructured":"Gao M, Bhatia K, Kapoor A, et al. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(4): e245135.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1908_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.","journal-title":"PLoS Med"},{"key":"1908_CR32","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"1908_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143(17):1673\u201386.","journal-title":"Circulation"},{"key":"1908_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"key":"1908_CR35","unstructured":"Rohatgi A. WebPlotDigitizer Version 4.7 (https:\/\/automeris.io\/WebPlotDigitizer). 2024. Accessed 06 Jun 2024."},{"key":"1908_CR36","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"issue":"2","key":"1908_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/pds.1234","volume":"16","author":"D Dobre","year":"2007","unstructured":"Dobre D, van Jaarsveld CHM, deJongste MJL, et al. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2007;16(2):152\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"1908_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","volume":"10","author":"EF Lewis","year":"2017","unstructured":"Lewis EF, Claggett BL, McMurray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10(8): e003430.","journal-title":"Circ Heart Fail"},{"issue":"37","key":"1908_CR39","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. EHJ. 2023;44(37):3627\u201339.","journal-title":"EHJ"},{"issue":"3","key":"1908_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001937","volume":"9","author":"EF Lewis","year":"2016","unstructured":"Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2016;9(3): e001937.","journal-title":"Circ Heart Fail"},{"issue":"12","key":"1908_CR41","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/ejhf.2738","volume":"24","author":"A Chandra","year":"2022","unstructured":"Chandra A, Polanczyk CA, Claggett BL, et al. Health-related quality of life outcomes in PARAGON-HF. Eur J Heart Fail. 2022;24(12):2264\u201374.","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"1908_CR42","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1001\/jama.2021.18463","volume":"326","author":"B Pieske","year":"2021","unstructured":"Pieske B, Wachter R, Shah SJ, et al. Effect of Sacubitril\/Valsartan versus standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial. JAMA. 2021;326(19):1919\u201329.","journal-title":"JAMA"},{"key":"1908_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0002-8703(97)70125-X","volume":"134","author":"P Faggiano","year":"1997","unstructured":"Faggiano P, D\u2019Aloia A, Gualeni A, et al. Assessment of oxygen uptake during the 6-minute walking test in patients with heart failure: preliminary experience with a portable device. Am Heart J. 1997;134:203\u20136.","journal-title":"Am Heart J"},{"issue":"5","key":"1908_CR44","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/heart.88.5.538","volume":"88","author":"JG Lainchbury","year":"2002","unstructured":"Lainchbury JG, Richards AM. Exercise testing in the assessment of chronic congestive heart failure. Heart. 2002;88(5):538\u201343.","journal-title":"Heart"},{"key":"1908_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2021.05.005","volume":"239","author":"MR Dos Santos","year":"2021","unstructured":"Dos Santos MR, de Alves MJ, et al. Sacubitril\/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: a randomized, double-blind, active-controlled study. Am Heart J. 2021;239:1\u201310.","journal-title":"Am Heart J"},{"issue":"12","key":"1908_CR46","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1002\/ejhf.2355","volume":"23","author":"M Halle","year":"2021","unstructured":"Halle M, Sch\u00f6bel C, Winzer EB, et al. A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan versus enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study. Eur J Heart Fail. 2021;23(12):2073\u201382.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"1908_CR47","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1111\/jgs.14940","volume":"65","author":"B Upadhya","year":"2017","unstructured":"Upadhya B, Hundley WG, Brubaker PH, et al. Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. J Am Geriatr Soc. 2017;65(11):2374\u201382.","journal-title":"J Am Geriatr Soc"},{"issue":"1S","key":"1908_CR48","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.amjcard.2017.05.013","volume":"120","author":"B Staels","year":"2017","unstructured":"Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Cardiol. 2017;120(1S):S28-36.","journal-title":"Am J Cardiol"},{"issue":"15","key":"1908_CR49","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1908_CR50","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/ajh\/hpz016","volume":"32","author":"L Shi","year":"2019","unstructured":"Shi L, Zhu D, Wang S, et al. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload. Am J Hypertens. 2019;32(5):452\u20139.","journal-title":"Am J Hypertens"},{"issue":"11","key":"1908_CR51","doi-asserted-by":"publisher","first-page":"E300","DOI":"10.1093\/eurjpc\/zwab203","volume":"29","author":"AE Berezin","year":"2022","unstructured":"Berezin AE. Plausible effects of sodium-glucose cotransporter-2 inhibitors on adverse cardiac remodelling. Eur J Prev Cardiol. 2022;29(11):E300\u20132.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"1908_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","volume":"4","author":"KA Connelly","year":"2019","unstructured":"Connelly KA, Zhang Y, Visram A, et al. Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. JACC Basic Transl Sci. 2019;4(1):27\u201337.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"1908_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11886-012-0267-9","volume":"14","author":"DK Moser","year":"2012","unstructured":"Moser DK, Dickson V, Jaarsma T, et al. Role of self-care in the patient with heart failure. Curr Cardiol Rep. 2012;14(3):265\u201375.","journal-title":"Curr Cardiol Rep"},{"key":"1908_CR54","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2147\/PPA.S410371","volume":"17","author":"AS Jarab","year":"2023","unstructured":"Jarab AS, Al-Qerem WA, Hamam HW, et al. Medication adherence and its associated factors among outpatients with heart failure. Patient Prefer Adherence. 2023;17:1209\u201320.","journal-title":"Patient Prefer Adherence"},{"key":"1908_CR55","doi-asserted-by":"publisher","first-page":"e002606","DOI":"10.1161\/JAHA.115.002606","volume":"5","author":"TM Ruppar","year":"2016","unstructured":"Ruppar TM, Cooper PS, Mehr DR,  et al.  Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta\u2010analysis of controlled trials. J Am Heart Assoc. 2016;5:e002606. https:\/\/doi.org\/10.1161\/JAHA.115.002606.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1908_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/JCN.0000000000000427","volume":"33","author":"JR Wu","year":"2018","unstructured":"Wu JR, Moser DK. Medication adherence mediates the relationship between heart failure symptoms and cardiac event-free survival in patients with heart failure. J Cardiovasc Nurs. 2018;33(1):40.","journal-title":"J Cardiovasc Nurs"},{"key":"1908_CR57","doi-asserted-by":"publisher","first-page":"ehad655.971","DOI":"10.1093\/eurheartj\/ehad655.971","volume":"44","author":"R Zhang","year":"2023","unstructured":"Zhang R, Mamza JB, Baruah R, et al. Initiation, titration, and discontinuation\u2014utilization of heart failure medicines in England (EVOLUTION HF UK). European Heart J. 2023;44:ehad655.971. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.971.","journal-title":"European Heart J"},{"issue":"10","key":"1908_CR58","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317.","journal-title":"Diabetologia"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01908-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:02:50Z","timestamp":1748592170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01908-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1908"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01908-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors report no relationships that could be construed as a conflict of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}